https://endpoints.news/biontech-oncoc4s-antibody-more-than-halves-risk-of-death-in-phase-3-lung-cancer-trial/
BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trial
Dec 8, 2025 - BioNTech and OncoC4 shared positive survival data from a late-stage trial of their drug candidate in lung cancer that was previously hit with a partial hold by...
halves riskbiontechantibody
https://uihc.org/childrens/news/hemodynamic-screening-halves-risk-death-or-severe-brain-bleed-very-premature-babies
Hemodynamic screening halves risk of death or severe brain bleed in very premature babies | Stead...
halves risksevere braindeath